Skip to main content

Table 5 Neutralization potential of anti-V3 scFvs against a panel of pseudoviruses and primary isolates

From: A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C

Virus

Clade

3E6B

3E7B

scFv (HepB)

1418

92RW

A

45

>100

>150

>150

SF162

B

115

>100

>150

>150

QZ4589

B

50

>100

>150

>150

AIIMS 261

C

110

45

>150

>150

Du 422

C

>150

>100

>150

>150

ZM 53

C

>150

>100

>150

>150

  1. The cross neutralizing activities of two anti-V3 scFv clones against a panel of subtype-A, B, C viruses that are listed on the left. The numerical values in the table represent the concentration (μg/ml) of scFvs at which 50% neutralization titers (IC50) was reached. AIIMS 261 is the primary isolate generated in our lab from a HIV-1 clade C infected patient. scFv (HepB) is an scFv against the Hepatitis B surface antigen (negative control) and 1418 is human antibody to parvovirus (negative control). Each experiment was performed at least two independent times.